Phibro Animal Health Affirms 2024 Adj. EPS And Net Sales Guidance
Portfolio Pulse from Benzinga Newsdesk
Phibro Animal Health has reaffirmed its fiscal year 2024 guidance, projecting net sales between $980 million to $1.020 billion, adjusted EBITDA of $106 million to $112 million, adjusted net income of $42 million to $47 million, and an adjusted diluted EPS of $1.04 to $1.16.
February 07, 2024 | 10:21 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Phibro Animal Health reaffirms its FY2024 financial guidance, indicating confidence in its future performance.
Reaffirming financial guidance often signals to investors that a company is on track to meet or exceed its financial targets, which can positively influence investor sentiment and potentially lead to an increase in stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100